ClinicaliQ Trial Snapshot
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients — Active Not Recruiting • Phase III • Oncology • NCT03049189.
- Review the linked registry entry for study design, population, endpoints, and operational status.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET). Conditions: Neuroendocrine Tumors Interventions: 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution Lead Sponsor: ITM Solucin GmbH Planned Enrollment: 324 participants